相关实验视频

Updated: Feb 28, 2026

Competing-Risk Nomogram for Predicting Cancer-Specific Survival in Multiple Primary Colorectal Cancer Patients after Surgery

Competing-Risk Nomogram for Predicting Cancer-Specific Survival in Multiple Primary Colorectal Cancer Patients after Surgery

Published on: September 27, 2024

在晚期卵巢癌中预测子最佳细胞减少模型的外部评估

Anna Serra Rubert^1,2, Maria Victoria Ibañez Gual³, Maria Teresa Climent Martí^1,2

¹Department of Gynecology and Obstetrics, University General Hospital of Castelló, 12004 Castelló, Spain.

Diagnostics (Basel, Switzerland)

|February 27, 2026

概括

在晚期卵巢癌中进行次优化手术的预测模型的外部验证是具有挑战性的,因为新队列中的次优化手术较少. 这表明该模型有效指导患者选择,间接改善手术结果.

科学领域:

妇科瘤学妇科瘤学
手术瘤学手术瘤学
预测建模预测建模

背景情况:

先进的卵巢癌手术旨在进行完整的细胞减少.
预测模型可以估计不完整手术的可能性.
外部验证对于模型通用性至关重要.

研究的目的:

在先进的卵巢癌中对次优化手术的预测模型进行外部验证.
评估模型预测不完整的细胞还原手术的能力.
评估模型对手术结果的影响.

主要方法:

复杂的卵巢癌患者的回顾性队列比较.
使用前性队列 (2017-2023) 与对照队列 (2013-2016) 的验证.
预测模型 (R3,R4) 基于CT,腹腔镜和肠子子阻塞的腹膜癌症指数 (PCI).

主要成果:

实验组显示了显著较低的亚最佳细胞减少率 (4.8%与13.8%相比).
在实验组中,观察到的炎病例较少,并且没有肠子阻塞.
预测模型未能将少数不理想的手术确定为高风险病例.

结论:

由于次优化手术的发病率较低,统计外部验证是不可行的.
减少次优化手术可能表明选择偏差,经验丰富的团队避免高风险患者.
间接证据表明,该模型有效指导患者选择并改善手术结果.

关键词:

晚期的卵巢癌是晚期的卵巢癌腹腔内皮癌的发生预测模型是一个预测模型.初级外科手术是一项主要的手术.低于最佳的细胞减少.

更多相关视频

Murine Model for Non-invasive Imaging to Detect and Monitor Ovarian Cancer Recurrence

Murine Model for Non-invasive Imaging to Detect and Monitor Ovarian Cancer Recurrence

Published on: November 2, 2014

Heterotypic Three-dimensional In Vitro Modeling of Stromal-Epithelial Interactions During Ovarian Cancer Initiation and Progression

Heterotypic Three-dimensional In Vitro Modeling of Stromal-Epithelial Interactions During Ovarian Cancer Initiation and Progression

Published on: August 28, 2012

相关概念视频

Cancer Survival Analysis

Cancer Survival Analysis

Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...